Comment on "Somatostatin as Inflow Modulator in Liver-transplant Recipients With Severe Portal Hypertension: A Randomized Trial"

Ann Surg. 2021 Aug 1;274(2):e194-e195. doi: 10.1097/SLA.0000000000003679.

Authors

Ruoyang Shao^{1

2}, Chuan Liu^{1

3}, Yanna Liu^{1

2}, Hua Mao³, Xun Li¹, Xiaolong Qi¹

Affiliations

¹ CHESS Center, Institute of Portal Hypertension, The First Hospital of Lanzhou University, Lanzhou, China.
² Department of Hepatology Unit and Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
³ Department of Gastroenterology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.

PMID: 31714312
DOI: 10.1097/SLA.0000000000003679

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Humans
Hypertension, Portal*
Portal Pressure
Somatostatin*
Transplant Recipients

Substances

Somatostatin